1. Research Infrastructures
  2. Plateforme Immunomonitoring en Cancérologie

Plateforme Immunomonitoring en Cancérologie

CONTACT
Coordinates 43.29236346203756, 5.359133426541125
Contact name Daniel Olive
CIVIS Label No
Acronym PIC-PTA
Scientific domain

LS6_4 - Immune-related diseases - Immunity, Infection and Immunotherapy


 

LS6_11 - Innovative immunological tools and approaches, including therapi - Immunity, Infection and Immunotherapy


Keywords

Biomarkers


 

Cancer


 

Biotherapies


 

Innate immunity


 

Adaptive immunity


 

Monoclonal antibodies


 

Immunodeficiency


 

Malignant hemopathies


 

Solid tumors


 

Preclinical study


 

Phase I and Phase II Protocol


 

Microenvironment


 

Flow cytometry


 

Mass cytometry


 

Phenotyping


 

Identification of new targets


Partner institution

Aix-Marseille Université


Website No
Technical staff available No
Remote access details IBiSA is opened to the medical, scientific community as well as industry within the framework of projects related to the cancerology and immunology. Our clients are biotechnology and biopharmaceutical companies. Teams interested in using the platform can directly contact the scientific coordinator. All applications will be answered considering the staff availability and the concordance of the project with the platform capacities. The evaluation, validation, and selection of projects will be done by evaluated by a committee. Whatever the project, IBiSA offers an array of services from study design, development and validation, product testing and data analysis, and each stage beneficing from the expertise of the facility local staff.
Remote access available No
Open to external users No
Equipment IBiSA offers its expertise in immunology, signaling and analysis of the tumor microenvironment within the framework of fundamental and preclinical research projects on experimental models as well as clinical trials on humans. Arrays of expertise are on: -preclinical development and monitoring of immune reactions to biotherapies (vaccination, transplant, monoclonal antibodies), -identification of alterations in innate immunity linked to cancers, -analysis of immune responses directed against pathogens associated with immune deficiency. To enable the detailed characterization of rare cell populations, the platform has developed mass cytometry tools which currently allow the study of around forty biomarkers per cell. Multidimensional data analysis is possible thanks to the use of new analysis algorithms (tSNE, UMAP, Wishbone ...). This technology, implemented on the platform since 2018, has many applications in clinical studies (hematology, solid tumors) and in fundamental research with the possibility of highlighting new checkpoint inhibitory biomarkers to understand and anticipate patient responses to immunotherapies. As a result, IBiSA offers services such as: -manipulation of cells obtained from samples from patients (blood, marrow), healthy volunteers or cell lines, -phenotypic analysis of cell subpopulations by multiparametric flow cytometry and mass cytometry, -functional tests (cytotoxicity, proliferation, cytokine production) by flow cytometry - Cr51 cytotoxicity tests (T CD8 +, NK, Tgd ...) - Cytokines, chemokines quantification by Elisa or Luminex (multiplex), -RNA extraction for sequencing, -analysis of gene expression by RQ-PCRunctional analysis of T cells by ELISPOT - Statistical analyzes: survival analysis, prognostic and predictive biomarkers, correlation of biological / clinical parameters - Bioinformatics analysis of high dimensional flow cytometry and mass cytometry data with regard to clinical data.
Open access to updated information database No
Online booking system details Charte des Plateformes Technologiques Aix-Marseille (PTA): https://www.univ-amu.fr/system/files/2021-07/Charte%20PTF%20AMU%20M%C3%A0J21.docx.pdf
Online booking system available No
Description IBiSA is located on the Institute Paoli Calmettes campus in Marseille. The facility is opened to the medical and scientific community within the framework of projects related to cancerology and immunology. It is labelled IBiSA since 2008 and certified ISO 9001:2015 and NFX 50-900:2016 (specific to life science technology facilities). With its surface area of 250 m2, the facility includes different equipements/tools to develop research projects on the basis of fundamental immunology, cellular, and molecular biology. The facility notably designs, performs, and interprets the molecular and cellular tests that quantify and qualify the many facets of the immune response and in turn reduce the uncertainties about the development of these agents. Data from these tests also permit to explore of new directions that complement to the study of archived material from the tumor bank. Also, the facility team has a good expertise in tumor immunology (NK cells functions in hematological malignancies, breast cancer and congenital immunodeficiency, cells in AML and NHL, pDC), in signaling, (co-signaling molecules in hematological malignancies and solid tumors) and also in the analysis of tumor microenvironment. The equipments/tools include the following: -3 culture rooms (2 L1 and 1 L2) with laminar flow cabinets, optical microscopes, centrifuges for peripheral blood mononuclear cells isolation, incubators for any type of cell culture (cells isolated from patients including HIV, HBV and HCV infected patients or healthy donors and cell lines), -1 mass cytometer (Helios, Fluidigm, USA, acquired in 2018). Mass cytometry is a variation of conventional flow cytometry using metal tagged antibodies instead of fluorochromes and detection by time of flight of discrete masses of the metal tags. The high purity and choice of metal isotopes provide minimal background noise from signal overlap or endogenous cellular components. It can actually detect up to 37/40 parameters simultaneously in a single tube, accelerating biomarker discovery and drug screening, -1 FacsCanto II BD flow cytometer for analysis (3 lasers 405nm/488nm/633nm – 8 PMT) fitted with a tube conveying system (acquired in 2010, IBiSA, FEDER), -3 stations for data analysis (softwares: Diva, FlowJo, Kaluza), -1 station for high dimensional analysis ( tSNE, FlowSOM), -1 CTL immunospot 5 UV core analyser that supports both visible light assays (ELISpot) and fluorescence-based FluoroSpot assays. This technique is more sensitive than ELISA and let the detection of a single secreting cell (cytokine, antibody) among 1,000,000 cells, -1 Agilent Bioanalyser 2100 (acquired in 2007) to qualify (no DNA contamination, RNA integrity) and to quantify RNA samples before NGS or RQ-PCR. Platform specificities. The facility members closely collaborate with clinical departments and the Biobank of IPC, with the AP-HM, and has actually contracts with industrial partners (Cellectis, Innate Pharma, GlaxoSmithKline, Alderaan , Imcheck Therapeutics) as well as grants from academic institutions (ANRS, INCa, PACA region, DGOS) and research institutes (Calym, Pioneer). The team is headed by Daniel Olive (PU/PH) and include 2 project leaders (MCU/PH), 1 Lab manager, 1 post-doctoral fellow, 5 engineers, and 3 technicians.